

The ALK therapy portfolio – the idea behind

At ALK, we want to give every patient the opportunity to receive an **effective therapy** and to experience long-term relief from allergy symptoms. To achieve this, we draw on our experience from almost 100 years of research and development. Our goal is to **make life easier for people with allergies**. We accomplish this thanks to our portfolio of high-quality products, a service-oriented business model and a team of committed employees.

The 5 guiding principles of ALK:

To ensure that allergy sufferers and allergy specialists gain maximum benefit from allergy immunotherapy, we employ the following **5 guiding principles** when developing our products:

① Natural allergens

Numerous high-quality clinical studies have proven that native, i.e. natural, non-chemically modified allergens are highly effective and have a good safety profile.¹

② From Mix to Mono

For pollen products, ALK consistently employs the concept of mono-allergen products (e.g. birch active substance in ITULAZAX®, ALUTARD SQ® and SOLUPRICK SQ®¹), which studies have proven to be clinically effective.²⁻³

③ Perennial therapy

ALK's therapeutic regimen is based on the principle of regular administration of high-dose allergen products throughout the year, as this pattern is more effective than pre-seasonal treatments due to the high cumulative allergen dose.⁴

④ Straightforward and user-friendly

Using ALK products should be as easy and intuitive as possible for both patients and doctors. Effectiveness, good tolerability and a high degree of patient satisfaction are achieved by combining established and innovative procedures.

⑤ Ongoing optimisation through continuous research

With the help of research and innovative studies, the allergen tablets and ALUTARD SQ®, in particular, are subject to constant improvement as product lines – with indication extensions (e.g. for children and adolescents or contemporary updosing regimes).

1. Pfaar et al. Leitlinie zur (allergen-)spezifischen Immuntherapie bei IgE-vermittelten allergischen Erkrankungen. Allergo J Int. 2014;23(8):282-319. 2. Current information for Health Care Professionals for ITULAZAX®, ALUTARD SQ®, and SOLUPRICK®, see www.swissmedicinfo.ch. 3. Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017 Dec;140(6):1485-1498. 4. Jutel M et al., International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb;137(2):358-68.



Allergy solutions
for life

The ALK therapy portfolio – evidence based, effective and safe

	Grass	Birch/tree pollen	Mites	Pet hair	Venom
SCIT 	 From 5 years	 From 5 years	 From 5 years	 From 5 years	 From 5 years
SLIT 	 From 5 years	 From 12 years	 From 12 years		

Current Information for Health Care Professionals for ALUTARD SQ®, GRAZAX®, ITULAZAX® and ACARIZAX®, see www.swissmedinfo.ch

✓ approved by authorities ✓ reimbursed by health insurances ✓ suitable for perennial therapy ✓ SQ standardised

We are looking forward to answering your questions



Franziska Haldimann
 Swiss Plateau and
 Northwestern Switzerland
 Phone 079 102 48 38
franziska.haldimann@alk.net



Katharina Diethelm
 Zurich and
 Eastern Switzerland
 Phone 079 102 48 60
katharina.diethelm@alk.net



Eric Dreyer
 French and Italian-
 speaking Switzerland
 Phone 079 102 57 54
eric.dreyer@alk.net

**We are
 here
 for you!**

ALK
 Chriesbaumstrasse 6
 CH-8604 Volketswil
 Tel. +41 44 908 21 00
 Fax +41 44 908 21 09
infoch@alk.net
www.alk.net/ch

